Form 4: SpringWorks Therapeutics Director Disposes of All Holdings Following $47.00 Per Share Merger with Merck KGaA

SpringWorks Therapeutics, Inc. Director Alan Fuhrman has disposed of all his common stock and stock options, totaling 24,727 shares and 78,755 options, respectively, as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.

Summary

• Alan Fuhrman, a Director of SpringWorks Therapeutics, Inc. (SWTX), reported the disposition of all his beneficial ownership in the company's securities.
• The disposition occurred on July 1, 2025, as a direct result of the Agreement and Plan of Merger, dated April 27, 2025, between SpringWorks Therapeutics, Inc., Merck KGaA, Darmstadt, Germany ("Parent"), and EMD Holdings Merger Sub, Inc. ("Merger Sub").
• Under the Merger Agreement, Merger Sub merged with and into SpringWorks Therapeutics, Inc., with the Issuer surviving as a wholly owned subsidiary of Parent.
• Each outstanding share of SpringWorks Therapeutics common stock was cancelled and automatically converted into the right to receive $47.00 in cash per share, without interest and subject to tax withholding.
• The reporting person disposed of 24,727 shares of common stock, which included 10,060 shares underlying restricted stock units (RSUs).
• All outstanding RSUs, whether vested or unvested, were cancelled and converted into a cash award equal to the product of the $47.00 Merger Consideration and the number of shares subject to the RSU.
• These cash-based RSU awards will generally vest according to their original terms, with a provision for 50% of each then-unvested tranche to vest on the nine-month anniversary of the closing date, subject to continued employment with Parent.
• The reporting person also disposed of 78,755 stock options with various exercise prices ranging from $18.00 to $44.77.
• Vested outstanding options were cancelled and converted into a cash amount equal to the product of the number of shares subject to the option and the excess of the $47.00 Merger Consideration over the option's per share exercise price.
• Unvested outstanding options were cancelled and converted into cash-based option awards, calculated similarly to vested options, with vesting generally following original terms and a 50% vesting on the nine-month anniversary for unvested tranches, subject to continued employment.
• Any outstanding option with an exercise price greater than $47.00 was cancelled at the effective time for no consideration or payment.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for shareholders who received a fixed cash premium for their shares. While out-of-the-money options were cancelled, the overall transaction provides a clear and positive liquidity event for most equity holders. The company's independent existence ends, which is neutral from a business operations perspective but positive for shareholders receiving the premium.

Positives

• Shareholders of SpringWorks Therapeutics, Inc. received a cash consideration of $47.00 per share, providing liquidity and a defined return on their investment.
• Holders of in-the-money stock options and restricted stock units received cash or cash-based awards, monetizing their equity incentives.
• The merger provides a clear exit strategy for investors in SpringWorks Therapeutics, Inc.

Negatives

• Stock options with an exercise price greater than the $47.00 Merger Consideration were cancelled for no consideration, resulting in a loss for holders of these out-of-the-money options.
• SpringWorks Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary of Merck KGaA.
• The continued vesting of cash-based RSU and option awards is contingent upon the holder's continued employment with Parent, introducing an employment risk for full realization of these awards.

Risks

• The continued vesting of cash-based RSU awards and cash-based option awards is subject to the applicable holder's continued employment with Parent through the specified vesting dates, including the nine-month anniversary of the closing date for a 50% vesting of unvested tranches.

Future Outlook

SpringWorks Therapeutics, Inc. is now a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany. The future outlook for the former equity holders is primarily tied to the cash consideration received and the vesting of any remaining cash-based equity awards, which are contingent on continued employment with the Parent company.

Management Comments

• The filing reflects the execution of the terms of the Agreement and Plan of Merger, dated April 27, 2025, which resulted in the cancellation and conversion of outstanding common stock, restricted stock units, and stock options into cash or cash-based awards.

Industry Context

This transaction represents a common occurrence in the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines and market presence. Such mergers often provide significant liquidity events for the acquired company's shareholders and integrate promising assets into the acquirer's portfolio.

Comparison to Industry Standards

• The merger structure, involving a cash-out of shares and conversion of equity awards into cash or cash-based awards, is a standard approach for acquisitions in the pharmaceutical and biotechnology industries.
• The treatment of in-the-money options and RSUs, converting them to cash or cash-equivalent awards, aligns with typical merger agreements designed to compensate employees for their vested and unvested equity.
• The cancellation of out-of-the-money options for no consideration is also a standard practice in such transactions, as these options hold no intrinsic value at the merger price.

Stakeholder Impact

• Shareholders: Received $47.00 cash per share, providing a definitive return on investment.
• Employees (including the reporting person): Equity awards were converted to cash or cash-based awards, with continued vesting contingent on employment with the acquiring entity, Merck KGaA.

Next Steps

• The cash-based RSU and option awards will continue to vest in accordance with their original terms, with a special 50% vesting on the nine-month anniversary of the merger closing date for unvested tranches, subject to continued employment with Merck KGaA.
• SpringWorks Therapeutics, Inc. will operate as a wholly owned subsidiary of Merck KGaA, integrating its operations and pipeline into the larger parent company.

Key Dates

Keywords

Merger, Acquisition, SEC Form 4, Insider Transaction, Beneficial Ownership, SpringWorks Therapeutics, SWTX, Merck KGaA, Stock Options, Restricted Stock Units, RSUs, Cash Consideration, Corporate Action, Biotechnology, Pharmaceuticals